Adjuvant progestagens for endometrial cancer.

Background: Endometrial cancer is the most common genital tract carcinoma among women in developed countries, with most women presenting with stage 1 disease. Adjuvant progestagen therapy has been advocated following primary surgery to reduce the risk of recurrence of disease.

Objectives: To evaluate the effectiveness and safety of adjuvant progestagen therapy for the treatment of endometrial cancer.

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.

This is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the immunogenicity, clinical efficacy, and safety of prophylactic HPV vaccines in females. The assessment of clinical efficacy will address protection against HPV infection (for homologous and heterologous HPV types), against re-infection, against cervical cancer and its precursors (high-grade CIN (grade 2 or grade 3), adenocarcinoma in situ) in women previously not exposed to HPV infection (negative at enrolment for both HPV DNA and antibodies against the vaccine HPV types).

Interventions for preventing blood loss during the treatment of cervical intraepithelial neoplasia.

Background: Cervical intraepithelial neoplasia (CIN) is the most common pre-malignant lesion. Surgical treatments for CIN are commonly associated with blood loss.

Objectives: To assess the effectiveness and safety of interventions for preventing blood loss during the treatment of CIN.

Surgery for cervical intraepithelial neoplasia.

Background: Cervical intraepithelial neoplasia (CIN) is the most common pre-malignant lesion. Atypical squamous changes occur in the transformation zone of the cervix with mild, moderate or severe changes described by their depth (CIN 1, 2 or 3). Cervical intraepithelial neoplasia is treated by local ablation or lower morbidity excision techniques.